Verenigde Staten - Engels - NLM (National Library of Medicine)

sun pharmaceutical industires inc. - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risk summary available data on use of risedronate sodium in pregnant women are insufficient to inform drug-associated risk of adverse maternal or fetal outcomes. discon

Verenigde Staten - Engels - NLM (National Library of Medicine)

northstar rxllc - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risk summary available data on use of risedronate sodium in pregnant women are insufficient to inform drug-associated risk of adverse maternal or fetal outcomes. discon

Australië - Engels - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risedronate sodium, quantity: 35 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; iron oxide yellow; macrogol 400; hypromellose; titanium dioxide; iron oxide red; microcrystalline cellulose - treatment of osteoporosis. treatment of glucocorticoid induced osteoporosis. preservation of bone mineral density in patients on long-term corticosteroid therapy

Ierland - Engels - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - risedronate sodium hemipentahydrate - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid

Ierland - Engels - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - risedronate sodium hemipentahydrate - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid

Ierland - Engels - HPRA (Health Products Regulatory Authority)

zaklad farmaceutyczny adamed pharma s.a. - risedronate sodium - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid

Ierland - Engels - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - risedronate sodium - film-coated tablet - 5 milligram(s) - bisphosphonates; risedronic acid

Ierland - Engels - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - risedronate sodium - film-coated tablet - 30 milligram(s) - bisphosphonates; risedronic acid

Ierland - Engels - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd, - risedronate sodium - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - risedronate sodium - oral tablet - 35mg